"Antimetabolites" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways. (From AMA Drug Evaluations Annual, 1994, p2033)
| Descriptor ID |
D000963
|
| MeSH Number(s) |
D27.505.519.186 D27.888.569.042
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antimetabolites".
Below are MeSH descriptors whose meaning is more specific than "Antimetabolites".
This graph shows the total number of publications written about "Antimetabolites" by people in this website by year, and whether "Antimetabolites" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 2 | 2 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 2 | 3 |
| 2005 | 1 | 0 | 1 |
| 2010 | 2 | 1 | 3 |
| 2013 | 1 | 2 | 3 |
| 2014 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antimetabolites" by people in Profiles.
-
Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series. J Immunother Cancer. 2024 01 31; 12(1).
-
d-Glucose- and d-mannose-based antimetabolites. Part 4: Facile synthesis of mono- and di-acetates of 2-deoxy-d-glucose prodrugs as potentially useful antimetabolites. Carbohydr Res. 2023 Sep; 531:108861.
-
Metabolic preconditioning in CD4+ T cells restores inducible immune tolerance in lupus-prone mice. JCI Insight. 2021 10 08; 6(19).
-
Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. Intensive Care Med. 2021 11; 47(11):1258-1270.
-
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Br J Haematol. 2021 11; 195(3):378-387.
-
KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer. Cancer Cell. 2020 04 13; 37(4):599-617.e7.
-
Current and Emerging Pharmaceutical Therapies for Noninfectious Uveitis. Int Ophthalmol Clin. 2019; 59(1):111-126.
-
D-Cycloserine augmentation of cognitive behavior therapy for pediatric OCD: Predictors and moderators of outcome. J Affect Disord. 2018 12 01; 241:454-460.
-
Ambient temperature influences the neural benefits of exercise. Behav Brain Res. 2016 Feb 15; 299:27-31.
-
CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. Eur Respir J. 2015 Dec; 46(6):1740-50.